Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.

Billings FT, Balaguer JM, C Y, Wright P, Petracek MR, Byrne JG, Brown NJ, Pretorius M
Clin Pharmacol Ther. 2012 91 (6): 1065-73

PMID: 22549281 · PMCID: PMC3822756 · DOI:10.1038/clpt.2011.356

The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blockade (ARB) on fibrinolysis and inflammation after cardiopulmonary bypass (CPB) are uncertain. This study tested the hypothesis that ACE inhibition enhances fibrinolysis and inflammation to a greater extent than ARB in patients undergoing CPB. One week to 5 days before surgery, patients were randomized to ramipril 5 mg/day, candesartan 16 mg/day, or placebo. ACE inhibition increased intraoperative bradykinin and tissue-type plasminogen activator (t-PA ) concentrations as compared to AR B. Both ACE inhibition and AR B decreased the need for plasma transfusion relative to placebo, but only ACE inhibition decreased the duration of hospital stay. Neither ACE inhibition nor AR B significantly affected concentrations of plasminogen activator inhibitor-1 (PAI -1), interleukin (IL )-6, IL -8, or IL -10. ACE inhibition enhanced intraoperative fibrinolysis without increasing the likelihood of red-cell transfusion. By contrast, neither ACE inhibition nor ARB affected the inflammatory response. ACE inhibitors and ARBs may be safely continued until the day of surgery.

MeSH Terms (24)

Aged Angiotensin-Converting Enzyme Inhibitors Angiotensin II Type 1 Receptor Blockers Benzimidazoles Blood Transfusion Bradykinin Cardiopulmonary Bypass Endpoint Determination Female Fibrinolysis Hematocrit Hospital Mortality Humans Inflammation Interleukins Length of Stay Male Middle Aged Monitoring, Intraoperative Perioperative Care Postoperative Complications Ramipril Tetrazoles Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities: